Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 50,312	$ 62,478
Short-term restricted cash	705	1,034
Prepaid expenses and other current assets	2,845	6,344
Refundable tax credit	210	1,276
Total current assets	54,072	71,132
Operating lease right-of-use assets	2,616	3,331
Other assets	444	507
Total assets	57,132	74,970
Current liabilities:
Current portion of debt	207	208
Accounts payable	1,340	1,495
Accrued expenses	7,366	9,066
Operating lease liabilities — current	1,173	1,751
Total current liabilities	10,086	12,520
Debt, net of current portion	168	168
Operating lease liabilities	1,934	2,395
Other liabilities	0	16
Total liabilities	12,188	15,099
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value: 100,000,000 shares authorized; 18,999,701 and 18,266,545 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	19	18
Additional paid-in capital	275,463	267,018
Accumulated deficit	(231,324)	(208,654)
Accumulated other comprehensive income	118	165
Total stockholders’ equity attributable to Millendo Therapeutics, Inc.	44,276	58,547
Equity attributable to noncontrolling interests	668	1,324
Total stockholders’ equity	44,944	59,871
Total liabilities and stockholders’ equity	$ 57,132	$ 74,970